NeuroOne Medical Technologies Corporation

NMTCNASDAQHealthcare● Active

$3.46

+$0.02(+0.58%)

Market Cap$29824771

P/E Ratio—

52W High$6.96

52W Low$3.276

Avg Volume38K

Open$3.43

Beta0.51

Overview

NeuroOne Medical Technologies Corporation (NMTC) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

nmtc · stock forecast · 3 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 3 Wall Street analysts in the past 3 months

Buy

3 analysts

consensus

Rating Breakdown

Strong Buy

Buy

Hold

Sell

Strong Sell

Total: 3 · Buy rate: 66.7%

12-Month Price Target

High

$3.00

Consensus

$3.00

-13.3% upside

Low

$3.00

Median: $3 · Last Close: $3.46

The NeuroOne Medical Technologies Corporation (NMTC) analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month NMTC price target is $3.00, representing -13.3% upside from the current price of $3.46.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

Date	Predicted Price	Change	Min	Max
2026-06-10	$3.29	↓ 5.00%	$3.22	$3.36

1-day model range: $3.22–$3.36. Peak: $3.36 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$4	—	$4	+9.1%
2028	$4	—	$4	+14.0%
2029	$4	—	$4	+16.6%
2030	$4	—	$4	+17.9%
2031	$4	—	$5	+18.6%

Confidence:Very Low

⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)20.8

MACDBEARISH

Moving Averages · NMTC · Jun 9, 2026

Simple Moving Average (SMA)

MA 5$3.48SELL

MA 10$3.60SELL

MA 20$3.92SELL

MA 50$4.35SELL

MA 100$4.54SELL

MA 200$4.65SELL

Current $NMTC · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$3.50SELL

EMA 10$3.62SELL

EMA 20$3.85SELL

EMA 50$4.19SELL

EMA 100$4.38SELL

EMA 200$4.43SELL

Current $NMTC · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:

Date	Brokerage	Action	Rating
2026-05-13	Ladenburg Thalmann	Maintains	Buy→Buy
2023-08-15	Alliance Global Partners	Maintains	Buy→Buy
2022-03-28	Craig-Hallum	Downgrade ↓	Buy→Hold
2021-12-03	Alliance Global Partners	Maintains	Buy→Buy
2021-11-15	Craig-Hallum	Maintains	Buy→Buy

Ladenburg Thalmann2026-05-13

Maintains

Buy→Buy

Alliance Global Partners2023-08-15

Maintains

Buy→Buy

Craig-Hallum2022-03-28

Downgrade ↓

Buy→Hold

Alliance Global Partners2021-12-03

Maintains

Buy→Buy

Craig-Hallum2021-11-15

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on NeuroOne Medical Technologies Corporation (NMTC) stock. Of the recent 5 rating actions, 0 were upgrades and 1 were downgrades. 3 analysts currently cover NMTC.

Analyst Recommendation Trends

Buy ratings1 → 1

Hold ratings0 → 0

Sell ratings0 → 0

NMTC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$11M

↓ 50.7% YoY

Revenue Next Year

$15M

↑ 34.3% YoY

EPS This Year

$-1.26

EPS Next Year

$-1.43

↑ 13.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast NMTC EPS of $-1.26 for the current fiscal year, based on estimates from 2 analysts. The NMTC revenue forecast is $11M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The NMTC stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus NMTC price target is $3.00 (-13.3% upside), with an analyst consensus of Buy.

The NMTC short-term stock prediction for tomorrow is $3.29 (-5.00%). The NMTC stock prediction for 2030 projects a range of $4–$4.

NeuroOne Medical Technologies Corporation trades on NASDAQ under the ticker NMTC. The NMTC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Earnings Revenue PE Ratio Financials Market Cap Insider Trades Dividends Price History

Frequently asked questions

NMTC forecast · 8 questions

According to 3 Wall Street analysts, the average 12-month NMTC price target is $3.00, with a high forecast of $3.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies -13.3% potential upside from the current price of $3.46.

NMTC price targetWhat is NMTC price targetNMTC analyst price targetNMTC 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.